For example, preclinical studies and clinical trials have confirmed that in OR-positive breast cancer, the addition of CDK4/6 inhibitors to endocrine therapy with an OR blocker that inhibits CCND1 activation yields more significant efficacy than [39, 40]. This evidence concerns the gene CCND1 and breast carcinoma.